The furthest along in the clinical process is an experimental vaccine developed by Hong Kong-listed CanSino Biologics Inc. and the Beijing Institute of Biotechnology, which is in phase 2. The other two being tested in humans are treatments developed separately by U.S. drugmakers Moderna Inc. and Inovio Pharmaceuticals Inc., according to a WHO document.
Progress is occurring at unprecedented speed in developing vaccines as the infectious pathogen looks unlikely to be stamped out through containment measures alone. The drug industry is hoping to compress the time it takes to get a vaccine to market -- usually about 10 to 15 years -- to within the next year.
Drugmakers big and small have jumped in to try to develop a vaccine, which would be the most effective way to contain the virus. Pharmaceutical giants likePfizer Inc.andSanofihave vaccine candidates in the preclinical stages, according to the WHO document.
CanSino said last month it received Chinese regulatory approval to start human trials of its vaccine. Cambridge, Massachusetts-based Moderna -- which has never put out a product -- received regulatory approval to move quickly to human trials in March, skipping the years of animal trials that are the norm in developing vaccines. Inovio began its human trials last week.